We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in 88 countries. For more information, visit ipsen.com. Pauta exclusiva para México: Clave de Autorización COFEPRIS: 243300201B1962 CONSULTE A SU MÉDICO. Pharmaceuticals, Specialty care: oncology, neuroscience, endocrinology, Research: peptides, toxins, …

Sectors: Pharmaceutical

Sofinnova Partners is a leading European VC firm in life sciences, specializing in healthcare and sustainability. Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential …

The health innovation network As a French leading biocluster, Lyonbiopole Auvergne-Rhône-Alpes aims to federate the actors of innovation, to connect and promote them internationally and to support the emergence and development of innovative technologies, products and services to address global healthcare challenges. Lyonbiopole Auvergne-Rhône-Alpes gathers a community of more than 250 members among which world-class leaders, innovative small and medium size companies, research centers and university hospitals. At the center of this ecosystem, Lyonbiopole brings its members altogether to imagine the future of medicine and to develop breakthrough healthTech innovation available for tomorrow’s patients.

Sectors: Biotechnology French Cluster Public business cluster

Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. …

Sectors: Pharmaceutical

Building a world-leading innovation ecosystem with Oxford University at its heart. Oxford University Innovation Limited is wholly owned by the University of Oxford. The company mission is to be the leading international technology transfer organisation, to transfer technology and expertise from the University of Oxford, to deliver value to all our clients, and to maximise social and economic benefits in a commercial manner. Oxford University Innovation helps staff and students to apply their expertise and research for wider social and economic benefit. Our role is to help University staff and students bring the benefits of their research and expertise to …

Sectors: Research

Our mission is to deliver the greatest possible impact to people through mRNA medicines. At Moderna, we believe messenger RNA, or mRNA, is the “software of life.” Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients. We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using …

Sectors: Biotechnology Pharmaceutical

Building a better world for everyone. Since it was established by Trinity College in 1970, the Cambridge Science Park has played a pivotal role in the “Cambridge Phenomenon” - the transformation of Cambridge from a market town with a world-class university to one of the hottest technology hotspots in the world. Today the 152-acre site is home to 100 science and technology companies ranging from spin-outs from the University of Cambridge to multinational companies seeking access to the brightest graduates and entrepreneurs from Cambridge’s diverse talent pool. Many are working on potentially life changing technologies from personalised medicines and non-invasive …

Sectors: Real Estate Startup accelerator & VC

Our people are our strength. And, together with over 53,000 colleagues, we're creating the next breakthrough in the world of health and innovation for both humans and animals. Are you ready to join us? #LifeForward Pharmaceuticals, Animal Health, Innovation, Research, Health Care, Improve Health, Biopharmaceuticals, and Contract Manufacturing

Sectors: Animal Health Pharmaceutical

Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. We design our products and services to serve the most essential human needs of health and nutrition. At the same time, we strive to address some of the world’s biggest challenges presented by a growing and aging global population. At Bayer, we’re committed to driving sustainable development and generate a positive impact with our businesses. Through the power of science, we’re pioneering new possibilities that advance life for all of us. That means reimagining how we care for ourselves and one another by …

Tags: DAX30 Sectors: Chemistry Pharmaceutical